Akebia Therapeutics (AKBA) Competitors $1.79 -0.07 (-3.76%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AKBA vs. URGN, PBYI, RAPT, MRNS, PRTA, XNCR, EVO, PRAX, DAWN, and RCUSShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include UroGen Pharma (URGN), Puma Biotechnology (PBYI), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), Prothena (PRTA), Xencor (XNCR), Evotec (EVO), Praxis Precision Medicines (PRAX), Day One Biopharmaceuticals (DAWN), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. UroGen Pharma Puma Biotechnology RAPT Therapeutics Marinus Pharmaceuticals Prothena Xencor Evotec Praxis Precision Medicines Day One Biopharmaceuticals Arcus Biosciences Akebia Therapeutics (NASDAQ:AKBA) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Does the MarketBeat Community prefer AKBA or URGN? Akebia Therapeutics received 50 more outperform votes than UroGen Pharma when rated by MarketBeat users. However, 73.83% of users gave UroGen Pharma an outperform vote while only 64.09% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformAkebia TherapeuticsOutperform Votes41464.09% Underperform Votes23235.91% UroGen PharmaOutperform Votes36473.83% Underperform Votes12926.17% Which has more risk & volatility, AKBA or URGN? Akebia Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Does the media favor AKBA or URGN? In the previous week, UroGen Pharma had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 9 mentions for UroGen Pharma and 5 mentions for Akebia Therapeutics. UroGen Pharma's average media sentiment score of 0.54 beat Akebia Therapeutics' score of 0.14 indicating that UroGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral UroGen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AKBA or URGN? Akebia Therapeutics presently has a consensus price target of $5.75, suggesting a potential upside of 221.23%. UroGen Pharma has a consensus price target of $48.38, suggesting a potential upside of 332.31%. Given UroGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe UroGen Pharma is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has better valuation and earnings, AKBA or URGN? Akebia Therapeutics has higher revenue and earnings than UroGen Pharma. Akebia Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$194.62M2.01-$51.92M-$0.23-7.78UroGen Pharma$82.71M3.17-$102.24M-$3.15-3.55 Do institutionals & insiders have more ownership in AKBA or URGN? 33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 4.1% of Akebia Therapeutics shares are owned by insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is AKBA or URGN more profitable? Akebia Therapeutics has a net margin of -27.07% compared to UroGen Pharma's net margin of -129.11%. Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-27.07% N/A -20.57% UroGen Pharma -129.11%N/A -47.94% SummaryUroGen Pharma beats Akebia Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$390.54M$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-7.784.4062.6013.00Price / Sales2.01377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book-7.789.636.455.92Net Income-$51.92M$154.43M$119.73M$225.73M7 Day Performance-7.73%-9.46%-5.13%-1.34%1 Month Performance34.59%-7.27%-2.71%1.15%1 Year Performance79.00%28.13%31.08%24.02% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics4.0582 of 5 stars$1.79-3.8%$5.75+221.2%+81.0%$390.54M$194.62M-7.78167URGNUroGen Pharma3.9752 of 5 stars$12.46+0.9%N/A-6.7%$292.19M$82.71M-3.96200PBYIPuma Biotechnology4.3836 of 5 stars$3.00-6.5%N/A-39.3%$147.27M$235.60M6.25185Positive NewsRAPTRAPT Therapeutics4.5971 of 5 stars$1.59-8.6%N/A-91.6%$55.52M$1.53M-0.5780Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMRNSMarinus Pharmaceuticals4.4479 of 5 stars$0.33-5.2%N/A-95.1%$18.01M$30.99M-0.13110Analyst ForecastShort Interest ↑Analyst RevisionNews CoveragePRTAProthena1.7433 of 5 stars$17.27-0.5%N/A-59.4%$928.78M$91.37M-6.96173Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageXNCRXencor3.604 of 5 stars$23.75+0.2%N/A+24.4%$1.66B$168.34M-7.42280Insider SellingEVOEvotec1.0235 of 5 stars$4.55+2.5%N/A-44.7%$1.61B$845.74M0.005,061Short Interest ↓News CoverageGap UpPRAXPraxis Precision Medicines1.7896 of 5 stars$84.09+1.3%N/A+398.0%$1.57B$2.45M-8.16110Insider SellingNews CoverageDAWNDay One Biopharmaceuticals1.7914 of 5 stars$15.26-2.4%N/A+13.6%$1.54BN/A-14.8260Insider SellingShort Interest ↑RCUSArcus Biosciences2.9087 of 5 stars$16.65-0.7%N/A+11.7%$1.52B$117M-5.29500 Related Companies and Tools Related Companies URGN Alternatives PBYI Alternatives RAPT Alternatives MRNS Alternatives PRTA Alternatives XNCR Alternatives EVO Alternatives PRAX Alternatives DAWN Alternatives RCUS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKBA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
